(SeaPRwire) –   SHANGHAI, March 21, 2026 — As World Water Day commences, WuXi Biologics restates its dedication to sustainability via responsible operations and high-efficiency, circular water usage practices that lower environmental impact.

WuXi Biologics has earned a spot on the CDP Water Security “A List” for three consecutive years, highlighting its industry-leading performance in environmental stewardship and operational transparency. This recognition reflects the company’s long-standing commitment to sustainable water management, including its consistent efforts to meet water usage targets, satisfy clients’ sustainability requirements, and continuously improve water management practices on an ongoing basis.

Major Progress in Systemic Water Management

WuXi Biologics actively supports the United Nations Sustainable Development Goal focused on clean water and sanitation (SDG 6), and has established a full-scope water management framework with clear targets and continuous progress monitoring. Using 2019 as the baseline year, the company set a target to reduce water consumption intensity by 30% by 2025, and fully reached this ambitious goal at the end of 2025, demonstrating the company’s unwavering commitment to excellence in water stewardship, and the success of its efforts to boost water efficiency and shrink its environmental footprint.

Rollout of WES Across Global Operations

To advance and support site-specific water stewardship and management across the entire organization, WuXi Biologics launched its Water Excellence Stewardship (WES) program in 2024, covering core focus areas including water governance, water balance, water quality, and safe water as well as environmental and personal hygiene (WASH). Through WES, each facility can evaluate its own sustainable water management performance, identify areas for improvement, and ensure alignment with international best practices. By the end of 2025, the WES program had been implemented at 10 of the company’s global sites.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “Natural resources form the foundation of human well-being, and are essential to the research, development and manufacturing of biologics. WuXi Biologics is dedicated to protecting the environment and advancing sustainability through responsible operations, while driving exemplary water stewardship efforts, and promoting universal access to water and sanitation services. As a global leader in Green CRDMO, we consistently deliver top-tier ESG performance, enable partners worldwide to meet their ESG commitments, and collaborate with all stakeholders to advance responsible practices across the entire value chain.”

As a member of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively promotes sustainability and has earned widespread recognition for its efforts. In addition to being named to the CDP “A List” for Water Security, the company was also included on the CDP “A List” for Climate Change and awarded an “A” rating in the CDP Supplier Engagement Assessment; granted an MSCI AAA Rating; presented with an EcoVadis Platinum Medal; listed in the Dow Jones Best-in-Class Indices; granted the highest possible negligible-risk rating by Sustainalytics, and named a top ESG performer in its industry and region by Sustainalytics for five consecutive years; selected as a constituent of the FTSE4Good Index Series; added to the Hang Seng Corporate Sustainability Benchmark Index; and awarded a Prime rating in the ISS ESG Corporate Rating.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that allow partners to discover, develop and produce biologics – from initial concept to full commercialization – for the benefit of patients across the world.

With more than 12,000 skilled employees across China, the United States, Ireland, Germany and Singapore, WuXi Biologics draws on its proprietary technologies and industry expertise to provide customers with efficient, cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III trials and 25 in commercial production.

WuXi Biologics views sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovation to deliver advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG) performance. Committed to creating shared value, it collaborates with all stakeholders to generate positive social and environmental impacts and promote responsible practices that empower the entire value chain.

To learn more about WuXi Biologics, please visit the company’s official website: www.wuxibiologics.com.

Contacts

ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

SOURCE WuXi Biologics